Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...
Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...
Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...
Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...
Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8539 ...
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8539 ...
If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.
Alvotech’s CEO highlighted the move as a significant step towards strengthening the company’s position in the biosimilars market and enhancing patient access to biologics globally. Acquisition ...
The Chosun Ilbo on MSN6d
Korean biotech firms race into $26 billion U.S. biosimilar marketSouth Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback